#	Pagina
attuale pagina	/open-h2020/projects/222519/index.html

Opendata, web and dolomites

CRUZIVAX SIGNED

Vaccine for prevention and treatment of Trypanosoma cruzi infection

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

CRUZIVAX project word cloud

Explore the words cloud of the CRUZIVAX project. It provides you a very rough idea of what is the project "CRUZIVAX" about.

stimulating clinical perform protect 11 vaccine decoy needle reports manufacturing infections rural formulation endemic chronicity models cellular treatment therapeutic active poor free worldwide morbidity conduct caused symptoms cardiac americas chimeric unnoticed antigen social performing locally infection humoral settings cgmp 30 structure strengthen interruption activation bridge efficacy preclinical facilitated migration latin cruzi volunteers million therapy benznidazole engineered suburban reducing carriers mice prophylactic chronic self acute critical immune gt sequences vi immunity primates largely cruzivax economic difficult 000 efficient immunogenicity mass healthy human parasitic 19 gap formulations chagas adjuvant health drug safety burden american dogs became mild lacking trial economics restricted limited 21 first usa carry pipeline countries trypanosoma combined proven trivalent disease profile

Project "CRUZIVAX" data sheet

The following table provides information about the project.

Coordinator	HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH Organization address address: INHOFFENSTRASSE 7 city: BRAUNSCHWEIG postcode: 38124 website: www.helmholtz-hzi.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Germany [DE]
Total cost	0 €
EC max contribution	8˙391˙240 € (0%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Two-Stage-RTD
Funding Scheme	RIA-LS
Starting year	2019
Duration (year-month-day)	from 2019-06-01 to 2024-05-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH Organization address address: INHOFFENSTRASSE 7 city: BRAUNSCHWEIG postcode: 38124 website: www.helmholtz-hzi.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BRAUNSCHWEIG)	coordinator	2˙070˙198.00
2	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Organization address address: RUE LEBLANC 25 city: PARIS 15 postcode: 75015 website: www.cea.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (PARIS 15)	participant	963˙795.00
3	ASA SPEZIALENZYME GMBH ASA SPEZIALENZYME GMBH Organization address address: AM EXER 19 C city: WOLFENBUTTEL postcode: 38302 website: www.asa-enzyme.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (WOLFENBUTTEL)	participant	951˙500.00
4	ATRC AURIGON TOXICOLOGIAI KUTATOKOZPONT KORLATOLT FELELOSSEGU TARSASAG ATRC AURIGON TOXICOLOGIAI KUTATOKOZPONT KORLATOLT FELELOSSEGU TARSASAG Organization address address: PALYA UTCA 2 city: DUNAKESZI postcode: 2120 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	HU (DUNAKESZI)	participant	863˙592.00
5	GENIBET - BIOPHARMACEUTICALS SA GENIBET - BIOPHARMACEUTICALS SA Organization address address: AVENIDA DA REPUBLICA QUINTA DO city: OEIRAS postcode: 2781 901 website: www.genibet.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (OEIRAS)	participant	861˙249.00
6	UNIVERSIDAD DE BUENOS AIRES UNIVERSIDAD DE BUENOS AIRES Organization address address: CALLE VIAMONTE 430 city: BUENOS AIRES postcode: 1053 website: www.uba.ar contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AR (BUENOS AIRES)	participant	745˙500.00
7	UNIVERSITEIT ANTWERPEN UNIVERSITEIT ANTWERPEN Organization address address: PRINSSTRAAT 13 city: ANTWERPEN postcode: 2000 website: www.ua.ac.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (ANTWERPEN)	participant	577˙302.00
8	UNIVERSIDADE NOVA DE LISBOA UNIVERSIDADE NOVA DE LISBOA Organization address address: CAMPUS DE CAMPOLIDE city: LISBOA postcode: 1099 085 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (LISBOA)	participant	442˙206.00
9	INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA INSTITUTO DE BIOLOGIA EXPERIMENTAL E TECNOLOGICA Organization address address: AVENIDA DA REPUBLICA QUINTO DO MARQUES city: OEIRAS postcode: 2781 901 website: www.ibet.pt contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (OEIRAS)	participant	352˙356.00
10	VAKZINE PROJEKT MANAGEMENT GMBH VAKZINE PROJEKT MANAGEMENT GMBH Organization address address: MELLENDORFER STRASSE 9 city: HANNOVER postcode: 30625 website: www.vakzine-manager.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (HANNOVER)	participant	310˙137.00
11	FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA Organization address address: C ROSSELLO 132 PLANTA 05 city: BARCELONA postcode: 8036 website: www.isglobal.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	253˙401.00

Map

Project objective

Chagas is a neglected disease endemic in 21 Latin-American countries caused by Trypanosoma cruzi. It is the largest parasitic disease burden in the Americas (>11,000,000 chronic infections) and the first cause of cardiac morbidity in poor rural/suburban areas. It became a worldwide concern as a result of mass migration with reports in 19 non-endemic areas (>1.3 million carriers in EU/USA). Treatment is difficult since acute infections have mild symptoms and remain largely unnoticed evolving to chronicity. Drug therapy is also long, often associated with side effects (10-30% interruption) and only active during early infection. The main objective of CRUZIVAX is to bridge the gap between preclinical and clinical development by performing preclinical and clinical phase 1 studies of a needle-free vaccine against T. cruzi with proven efficacy in preclinical models. The vaccine is based on a structure-engineered trivalent chimeric antigen lacking immune decoy sequences and an adjuvant promoting self-limited locally-restricted immune activation stimulating humoral and cellular immunity, which is expected to protect as prophylactic or therapeutic (combined with Benznidazole) vaccine. To achieve this CRUZIVAX will: (i) conduct preclinical studies in mice to assess immunogenicity and efficacy of different vaccine formulations in prophylactic and therapeutic settings, (ii) analyse the immunogenicity and efficacy of the best vaccine formulation in dogs and non-human primates, (iii) produce cGMP antigen and adjuvant by cost-efficient manufacturing (facilitated uptake by health systems with limited resources), (iv) perform a preclinical safety assessment of the vaccine, (v) conduct a phase 1 vaccine clinical trial in healthy volunteers, and (vi) carry out a health economics analysis to identify critical target-product profile parameters. The vaccine will strengthen the pipeline of products for Chagas disease, aimed at reducing disease burden and its social and economic impact.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CRUZIVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CRUZIVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More